

Title (en)

PRAMIPEXOLE FOR THE TREATMENT OF ADHD

Title (de)

PRAMIPEXOL ZUR BEHANDLUNG VON ADHD

Title (fr)

PRAMIPEXOL DESTINE AU TRAITEMENT DE LE THADA

Publication

EP 1416930 A1 20040512 (DE)

Application

EP 02762417 A 20020731

Priority

- DE 10137633 A 20010803
- EP 0208500 W 20020731

Abstract (en)

[origin: WO03013520A1] The invention relates to the use of 2-amino-4,5,6,7-tetrahydro-6-n-propylamino-benzothiazole, the (+) or (-) enantiomers thereof, the pharmacologically acceptable acid addition salts of the same, and hydrates and solvates for producing a pharmaceutical for the prevention and/or treatment of ADHD.

IPC 1-7

A61K 31/425; **A61P 25/00**

IPC 8 full level

C07D 277/82 (2006.01); **A61K 31/425** (2006.01); **A61K 31/428** (2006.01); **A61K 45/00** (2006.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)

A61K 31/425 (2013.01); **A61K 31/428** (2013.01); **A61P 25/00** (2017.12); **A61P 25/28** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 03013520A1

Citation (examination)

LAGOS P. ET AL: "Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 8, no. 2, 1 May 1998 (1998-05-01), pages 113 - 120, XP007906317, DOI: doi:10.1016/S0924-977X(97)00054-0

Cited by

EP2295040A1; EP2308464A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)

WO 03013520 A1 20030220; AR 035273 A1 20040505; CA 2453485 A1 20030220; DE 10137633 A1 20030220; EP 1416930 A1 20040512; JP 2005500368 A 20050106; MX PA04001001 A 20040420; UY 27408 A1 20030228

DOCDB simple family (application)

EP 0208500 W 20020731; AR P020102946 A 20020802; CA 2453485 A 20020731; DE 10137633 A 20010803; EP 02762417 A 20020731; JP 2003518529 A 20020731; MX PA04001001 A 20020731; UY 27408 A 20020802